In FocusA randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I
Under an Elsevier user license
open archive
Keywords
dalteparin
deep vein thrombosis
hemorrhage
oral direct thrombin inhibitor
ximelagatran
Cited by (0)
Copyright © 2003 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.